Betamethasone dipropionate with clotrimazole

What it is

This is a single cream (also sold as a lotion) that contains two different drugs: clotrimazole 1%, an azole antifungal, and betamethasone dipropionate, a potent corticosteroid. Each gram holds 10 mg of clotrimazole and 0.64 mg of betamethasone dipropionate, equivalent to 0.5 mg of betamethasone, in a water-based cream with mineral oil, white petrolatum, cetostearyl alcohol, propylene glycol and benzyl alcohol as preservative. It is prescription-only in the United States and is licensed only for people aged 17 and over.

What the research says

The antifungal half kills the dermatophyte; the steroid half suppresses the inflammation the fungus causes, which makes the rash look and feel better faster. Cochrane found that azole alone was slightly worse than an azole-plus-steroid combination for clinical cure at the end of treatment (RR 0.67, 95% CI 0.53 to 0.84, NNT 6) but that mycological cure, actually clearing the fungus, was no different at all (RR 0.99, 95% CI 0.93 to 1.05), and rated that evidence very low certainty for clinical cure. Cochrane also records that steroid-antifungal combinations are not recommended in any clinical guideline. The steroid is the problem: adrenal suppression on cosyntropin testing appeared in 39.5% and 47.1% of adolescents in two open-label trials, and the postmarketing record includes skin atrophy, striae and masked, persistent fungal infection.

Evidence grade: Disputed.

How it works

Drug class: Fixed-dose combination of an azole antifungal (clotrimazole 1%) and a high-potency topical corticosteroid (betamethasone dipropionate 0.05%)

Clotrimazole blocks a fungal enzyme that makes ergosterol, the sterol the fungal cell membrane needs, so the membrane fails and the fungus stops growing. Betamethasone dipropionate is a corticosteroid: it damps down the immune and inflammatory response in the skin, which is what reduces the redness and itch. The label concedes that the precise mechanism by which the corticosteroid helps in tinea is unknown, and the same immune suppression is what lets a fungal infection spread while looking better. (Source 1)

What it is used for

• The combination clears the rash's appearance a little faster than an azole alone (clinical cure RR 0.67 favouring the combination, NNT 6) but kills the fungus no better (mycological cure RR 0.99), on evidence Cochrane rated low to very low certainty. Cochrane notes that no clinical guideline recommends steroid-antifungal combinations, and that relapse rates could not be assessed. Evidence: disputed. (Source 2)
• The label says use under 17 is not recommended, and its own open-label trials in 12 to 16 year olds showed adrenal suppression in 39.5% and 47.1% of evaluable subjects. A Pediatrics case series found six children treated with the combination for 2 to 12 months with persistent or recurrent tinea corporis, mostly tinea faciei, which cleared once they were switched to a plain antifungal. That series was an uncontrolled retrospective review of six children’s records at one clinic, with no comparison group, and its authors put it no higher than that the combination "may be associated with persistent/recurrent infection". Evidence: harm. (Source 3)
• The label states flatly that use in diaper dermatitis is not recommended, and separately warns that diapers or plastic pants can act as an occlusive dressing, which is one of the named risk factors for suppressing the adrenal glands. Greenberg and colleagues reported that over half of prescriptions for the most widely used combination agent went to children under four. Evidence: not-supported. (Source 4)
• A review of the combination's clinical trial record found it less effective at clearing candidal and Trichophyton infections than single-agent antifungals. Clotrimazole's own resistance data note that resistance to azoles has been reported in some Candida species, while no resistant dermatophyte strains have been reported. Evidence: not-supported. (Source 5)
• Using a steroid on an unconfirmed rash is how tinea incognito arises: the fungal infection loses its typical ring shape, is mistaken for eczema, psoriasis or lupus, spreads, and resists treatment. A 2024 review describes delayed diagnosis, spread to critical body surfaces, resistance to antifungal drugs and increased costs, and states, without giving a figure, that it is more common in children. Evidence: harm. (Source 6)

Interactions

• Other topical or systemic corticosteroids, and anything that occludes the skin (dressings, diapers, plastic pants, tight clothing over the groin) (label): Corticosteroid exposure adds up, and occlusion multiplies absorption through the skin. The label's own list of what predisposes to adrenal suppression is high-potency steroids, large treatment surface areas, prolonged use, occlusive dressing, altered skin barrier, liver failure and young age, so stacking another steroid or covering the area pushes in the same direction. (Source 4)
• Any other immunosuppressive medicine, topical or systemic (narrative-review): Tinea incognito, the masked and spreading fungal infection, is described as arising from topical or systemic steroids or other immunosuppressive medications. Someone already on an immunosuppressant is therefore at the same risk from a steroid-containing antifungal cream. (Source 6)
• The eyes, mouth and vagina (route restrictions rather than a substance) (label): The cream is for external skin use only. Topical corticosteroids including betamethasone products have been linked in postmarketing reports to cataracts, glaucoma, raised intraocular pressure and central serous chorioretinopathy, and the label asks patients to report visual symptoms. (Source 4)

Stopping it

• Stopping is built into the licence, not left open: no longer than 2 weeks for tinea corporis or cruris, no longer than 4 weeks for tinea pedis. (Source 7)
• If adrenal suppression is found, the label's instruction is gradual withdrawal, less frequent application, or a switch to a weaker steroid, not an abrupt stop. (Source 4)
• Adrenal insufficiency can appear after treatment ends, not only during it, and children are at greater risk of that during and after withdrawal. (Source 3)
• Where the steroid has already masked a fungal infection, treatment of tinea incognito starts by stopping the steroid, then treating the fungus properly. (Source 6)
• The combination is not a drug of dependence and there is no withdrawal syndrome described for it; what stopping can unmask is the untreated or partly treated fungal infection underneath, which in one case series had persisted or recurred after 2 to 12 months of use. (Source 8)
• The last counselling bullet in the label cuts the other way from stopping early: the course is to be finished even if the rash has settled, and the trigger to go back to the prescriber is a lack of improvement at 1 week for tinea cruris or corporis, or 2 weeks for tinea pedis. (Source 9)

What goes wrong

Roughly two in five adolescents treated with the cream for ordinary tinea showed suppression of their adrenal glands on testing. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 43 evaluable subjects aged 12 to 16 in the tinea pedis trial and 17 in the tinea cruris trial.
• Who: Adolescents aged 12 to 16 years treated with the combination cream in open-label trials.
• How long: Standard treatment courses for tinea pedis and tinea cruris.
• Result: 17 of 43 (39.5%) evaluable paediatric subjects treated for tinea pedis and 8 of 17 (47.1%) treated for tinea cruris demonstrated adrenal suppression as determined by cosyntropin testing.
• Funding: Not stated in the label; these are the manufacturer's trials.

In open-label trials, 17 of 43 (39.5%) evaluable pediatric subjects (aged 12 to 16 years old) using clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) for treatment of tinea pedis demonstrated adrenal suppression as determined by cosyntropin testing. In another open-label trial, 8 of 17 (47.1%) evaluable pediatric subjects (aged 12 to 16 years old) using clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) for treatment of tinea cruris demonstrated adrenal suppression as determined by cosyntropin testing.

Even in healthy adults, two weeks of a large dose to the groin pushed morning cortisol down in three of eight subjects. (Source 4)

• Randomized trial, Low certainty.
• Size: 8 normal adult subjects.
• Who: Normal adult volunteers.
• How long: 7 g daily, twice a day, for 14 days to the crural (groin) area.
• Result: Three of the 8 subjects had low morning plasma cortisol during treatment; one of these had an abnormal cosyntropin test; the effect was transient and subjects recovered 1 week after stopping.
• Funding: Not stated in the label.

Three of the 8 normal subjects on whom clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) was applied exhibited low morning plasma cortisol levels during treatment. One of these subjects had an abnormal cosyntropin test.

Suppression of the adrenal axis can cause glucocorticoid insufficiency, Cushing's syndrome and high blood sugar, and can appear after treatment has stopped as well as during it. (Source 4)

• Official position, Moderate certainty.
• Size: Not quantified in this section.
• Who: Anyone using the cream; risk factors named are high-potency steroids, large treatment areas, prolonged use, occlusive dressing, altered skin barrier, liver failure and young age.
• How long: During treatment or after withdrawal of treatment.
• Result: No rate in this section; the label directs periodic evaluation for HPA axis suppression using the ACTH (cosyntropin) stimulation test.
• Funding: Not applicable.

can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or after withdrawal of treatment. Cushing's syndrome and hyperglycemia may also occur due to the systemic effect of corticosteroids while on treatment.

The documented skin harms of the steroid include thinning, permanent stretch marks, broken capillaries and loss of pigment. (Source 10)

• Case series, Very low certainty.
• Size: Spontaneous postmarketing reports from a population of uncertain size.
• Who: People using topical corticosteroids including this product.
• How long: Not stated.
• Result: No rates can be calculated. Reported local reactions are itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, skin atrophy, striae, miliaria, capillary fragility (ecchymoses), telangiectasia and sensitization; ophthalmic reactions include cataracts, glaucoma, raised intraocular pressure and central serous chorioretinopathy.
• Funding: Not applicable.

The following local adverse reactions have been reported with topical corticosteroids: itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, skin atrophy, striae, miliaria, capillary fragility (ecchymoses), telangiectasia, and sensitization (local reactions upon repeated application of product).

Children are at greater risk than adults of adrenal suppression and of skin thinning and stretch marks, and growth retardation and raised intracranial pressure have been reported. (Source 3)

• Case series, Low certainty.
• Size: Not quantified; postmarketing reports in paediatric patients on topical corticosteroids.
• Who: Children treated with topical corticosteroids.
• How long: Not stated.
• Result: No rates; reported events are HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension.
• Funding: Not applicable.

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are, therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin atrophy, including striae, when they are treated with topical corticosteroids.

In people over 65 the postmarketing record includes skin atrophy and rare skin ulceration. (Source 11)

• Case series, Very low certainty.
• Size: Not quantified; the clinical studies did not include enough people over 65 to compare.
• Who: Patients aged 65 and above.
• How long: Not stated.
• Result: No rates; reports of skin atrophy and rare reports of skin ulceration.
• Funding: Not applicable.

Postmarket adverse event reporting for clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) in patients aged 65 and above includes reports of skin atrophy and rare reports of skin ulceration.

A review of the combination's record concluded it is less cost-effective than antifungal monotherapy and may be inappropriate for children, with treatment failure, striae distensae, hirsutism and growth retardation reported in children. (Source 5)

• Expert review, not systematic, Low certainty.
• Size: A literature review of clinical trial data and adverse reactions, plus a two-month cost analysis of topical antifungal prescribing in one large midwestern staff-model health maintenance organisation.
• Who: Patients prescribed the combination for common cutaneous fungal infections; the harms described were in children.
• How long: Not applicable (review)
• Result: The combination accounted for more than 50% of topical antifungal expenditures when prescribed by primary care physicians but only 7% of topical antifungals prescribed by dermatologists.
• Funding: Not stated.

Limit of this finding: This was a literature review of previously published trial reports together with a cost analysis of prescribing records from one American health maintenance organisation over two months. It ran no trial of its own, so the harms it describes are reports gathered from other papers and the cost-effectiveness conclusion is the authors' judgement rather than a measured outcome. The source spells it "diproprionate" and "hirsuitism"; both are kept as published.

The most concerning adverse effects of Lotrisone were reported in children and included treatment failure, striae distensae, hirsuitism, and growth retardation. This combination was also reported to have decreased efficacy in clearing candidal and Trichophyton infections as compared to single-agent antifungals.

Six children treated with the combination for two to twelve months had persistent or recurrent tinea corporis that cleared only after switching to a plain antifungal. (Source 8)

• Case series, Very low certainty.
• Size: 6 children aged 4 to 11, identified from a six-month clinic registry review.
• Who: Children evaluated for tinea corporis, especially tinea faciei, in a university hospital paediatric dermatology clinic between January and June 2001.
• How long: Initial treatment with the combination cream for 2 to 12 months; response confirmed at least 1 month after clearing.
• Result: All 6 had been diagnosed clinically by their paediatrician and treated with the combination for 2 to 12 months; diagnosis was then confirmed by positive potassium hydroxide preparation and all cleared on oral or topical antifungals.
• Funding: Not stated.

Limit of this finding: Six children, no comparison group. This was a retrospective review of clinic records over a single six-month period at one hospital, and every child had already been treated with the combination before the dermatology clinic saw them. Nothing here shows how often this happens, or how often children treated with a plain antifungal would have done better; the authors put it no higher than "may be associated with". The source spells the drug "diproprionate".

All 6 children were diagnosed clinically by their pediatrician with tinea corporis and initially treated with clotrimazole 1%/betamethasone diproprionate 0.05% cream for 2 to 12 months.

Putting a steroid on a fungal infection produces tinea incognito: an infection that loses its typical appearance, is mistaken for other skin diseases, spreads and resists treatment. (Source 6)

• Expert review, not systematic, Low certainty.
• Size: Not quantified; a review of the literature.
• Who: People of all ages and genders, but more commonly children.
• How long: Not applicable.
• Result: No rates given; the review lists delayed diagnosis, spread of the infection to critical body surfaces, resistance to antifungal drugs, and increased costs due to prolonged hospitalisation and multiple treatment regimens.
• Funding: Independent; authors declare no conflicts of interest.

Limit of this finding: This is a narrative review: the authors summarise the published literature without a stated search method or pooled numbers. The statement that tinea incognito is more common in children is the review authors' own assertion with no figure attached, and should not be read as a measured rate.

Delayed diagnosis, spread of the infection to critical body surfaces, resistance to antifungal drugs, and increased costs due to prolonged hospitalization and multiple treatment regimens often complicate tinea incognito. It can affect individuals of all ages and genders, but it is more common in children.

Doctors who are not dermatologists prescribe the combination roughly seven times as often as dermatologists do, for the same infections. (Source 12)

• Survey study, Low certainty.
• Size: 4.1 million office visits for cutaneous fungal disease in the 1990-1994 National Ambulatory Medical Care Survey, 82% of them to nondermatologists.
• Who: Patients attending office-based physician visits in the United States for fungal skin infections.
• How long: Five survey years.
• Result: Nondermatologists prescribed combination agents at 34.1% of visits versus 4.8% for dermatologists (p=0.001); an estimated $24.9 million or $10.3 million would be saved annually if clotrimazole or ketoconazole respectively replaced the combination.
• Funding: Not stated.

Limit of this finding: This study counted prescriptions, not outcomes. It is a cross-sectional analysis of United States office-visit survey records from 1990 to 1994, and it measured no cure rates and no actual spending. The authors' phrase "less effective" is brought in from other literature rather than shown here, and the dollar savings are a projection of what might have happened if prescribing had changed, in mid-1990s money that is now about thirty years out of date.

Nondermatologists were more likely to prescribe combination agents (34.1%) than dermatologists (4.8%, p=0.001).

The label gives this product no contraindications at all, and no drug interaction section exists in any of the four product labels we parsed. (Source 9)

• Official position, Certainty not rated.
• Size: Four Structured Product Labels parsed (Fougera cream, Sun cream, Actavis cream, Sun lotion)
• Who: Not applicable.
• How long: Not applicable.
• Result: None of the four labels carries a Drug Interactions section (LOINC 34073-7). The absence of listed interactions is an absence of documentation, not evidence of safety, and the label still imposes hard limits: not more than 45 g a week, no occlusive dressings, not on the face or underarms, and a stop date.
• Funding: Not applicable.

Do not use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) on the face or underarms. • Do not use more than 45 grams of clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) per week.

Using it in pregnancy carries a documented signal for low birthweight, which is why the label tells pregnant women to use the smallest area and shortest duration possible. (Source 9)

• Official position, Low certainty.
• Size: Not quantified in the counselling section.
• Who: Pregnant and breastfeeding women.
• How long: Not stated.
• Result: No numbers in this section; the instruction is the smallest area of skin for the shortest duration possible, and not to apply it to the nipple and areola while breastfeeding.
• Funding: Not applicable.

Advise pregnant women that clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) may increase the risk of having a low birthweight infant and to use clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) on the smallest area of skin and for the shortest duration possible

The label's counselling instructions end by telling patients to report local reactions, and warn that skin reactions and thinning are likelier with covered or prolonged use. (Source 9)

• Official position, Low certainty.
• Size: Not quantified in this section.
• Who: Patients prescribed the cream.
• How long: Not stated here; the label's limits are 2 weeks for tinea corporis and cruris and 4 weeks for tinea pedis.
• Result: No rate given. The two risk factors named are occlusive use and prolonged use, and the reactions named are local reactions and skin atrophy.
• Funding: Not applicable.

Limit of this finding: The label gives no frequency for this, so it says what to watch for rather than how likely it is. The same counselling section prints "(base)as directed" with no space and double-spaces "that clotrimazole"; both are the label's own typesetting and have been kept.

Report any signs of local adverse reactions to the physician. Advise patients that local reactions and skin atrophy are more likely to occur with occlusive use or prolonged use.

What the evidence supports

The combination's own registration trials compared it only against each of its two ingredients, not against a modern antifungal, and reported appearance at a 3-to-5-day visit. (Source 13)

• Randomized trial, Low certainty.
• Size: Not stated in the label.
• Who: Subjects with tinea corporis, tinea cruris and tinea pedis.
• How long: First return visit 3 to 5 days after starting treatment for tinea corporis and cruris, 1 week for tinea pedis.
• Result: Better clinical response at the first return visit than clotrimazole cream; mycological cure rates as good as or better than clotrimazole cream; better clinical response and mycological cure than betamethasone dipropionate cream alone.
• Funding: Not stated in the label.

Limit of this finding: These are the label's own registration trials and the label reports no cure-rate numbers for them at all, only that the combination was "as good as, or better than" its two separate ingredients. The comparison was against clotrimazole and against betamethasone dipropionate, not against a modern antifungal such as terbinafine, and the first assessment was at 3 to 5 days, which measures how the rash looked rather than whether the fungus was gone.

subjects treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) showed a better clinical response at the first return visit than subjects treated with clotrimazole cream. In tinea corporis and tinea cruris, the subject returned 3 to 5 days after starting treatment, and in tinea pedis, after 1 week. Mycological cure rates observed in subjects treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) were as good as, or better than, in those subjects treated with clotrimazole cream.

Terbinafine and naftifine, plain antifungals, are the treatments the same Cochrane review found actually effective against placebo, with a number needed to treat of 3. (Source 14)

• Systematic review, Low certainty.
• Size: Five studies for terbinafine clinical cure; three studies for naftifine mycological cure; two studies for clotrimazole mycological cure.
• Who: People with proven tinea cruris or tinea corporis.
• How long: Mostly two to four weeks of treatment.
• Result: Terbinafine versus placebo clinical cure RR 4.51 (95% CI 3.10 to 6.56), NNT 3 (95% CI 2 to 4); naftifine 1% mycological cure RR 2.38 (1.80 to 3.14), NNT 3 (2 to 4); clotrimazole 1% mycological cure RR 2.87 (2.28 to 3.62), NNT 2 (2 to 3)
• Funding: Independent; no financial conflicts declared.

The pooled data suggest that the individual treatments terbinafine and naftifine are effective. Adverse effects were generally mild and reported infrequently.

Clotrimazole on its own has no reported dermatophyte resistance, so the argument for adding a steroid is comfort, not killing power. (Source 1)

• Lab study in cells, Low certainty.
• Size: Successive passages of Trichophyton mentagrophytes in vitro, plus clinical infection data.
• Who: Dermatophytes, not patients.
• How long: Not applicable.
• Result: No strains of dermatophytes with natural resistance to clotrimazole have been reported, and no single-step or multiple-step resistance developed during successive passages of Trichophyton mentagrophytes; resistance to azoles has been reported in some Candida species.
• Funding: Not stated in the label.

Strains of dermatophytes having a natural resistance to clotrimazole have not been reported. Resistance to azoles, including clotrimazole, has been reported in some Candida species.

What the evidence does not support

Cochrane records that no clinical guideline recommends steroid-antifungal combinations, and that it could not assess whether the infection comes back. (Source 14)

• Systematic review, Very low certainty.
• Size: 129 studies, 18,086 participants; 63 of the studies contained no usable or retrievable data.
• Who: People with tinea cruris or tinea corporis.
• How long: As above.
• Result: No effect estimate for relapse; the review states there was insufficient evidence to confidently assess relapse rates in the individual or combination treatments.
• Funding: Independent; no financial conflicts declared.

Although combinations of topical steroids and antifungals are not currently recommended in any clinical guidelines, relevant studies included in this review reported higher clinical cure rates with similar mycological cure rates at the end of treatment, but the quality of evidence for these outcomes was rated very low due to imprecision, indirectness and risk of bias. There was insufficient evidence to confidently assess relapse rates in the individual or combination treatments.

The short clinical trials captured almost none of this: the only common reaction recorded was pins and needles in 1.9% of patients. (Source 10)

• Randomized trial, Low certainty.
• Size: Not stated in the label's adverse reactions section.
• Who: Patients in the registration clinical trials.
• How long: The one to four week courses the label allows.
• Result: Paresthesia in 1.9% of patients; rash, oedema and secondary infection each at a frequency below 1%.
• Funding: Not stated in the label.

In clinical trials common adverse reaction reported for clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) was paresthesia in 1.9% of patients. Adverse reactions reported at a frequency < 1% included rash, edema, and secondary infection.

It is licensed only for three named dermatophytes and only in people 17 and over, so any wider use is outside the evidence that was reviewed. (Source 2)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Patients 17 years and older with symptomatic inflammatory tinea pedis, cruris or corporis.
• How long: Not applicable.
• Result: No numbers; a licensing boundary.
• Funding: Not applicable.

is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older.

If the rash has not improved after the first week or two, the label's instruction is to question the diagnosis rather than carry on. (Source 7)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Patients being treated for tinea with this cream.
• How long: Review at 1 week for tinea corporis or cruris, 2 weeks for tinea pedis.
• Result: Hard stop dates: not longer than 2 weeks for tinea corporis or cruris and not longer than 4 weeks for tinea pedis, and not more than 45 grams per week.
• Funding: Not applicable.

If a patient shows no clinical improvement after 1 week of treatment with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base), the diagnosis should be reviewed.

The label concedes it does not know how the steroid helps in tinea at all. (Source 15)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Not applicable.
• How long: Not applicable.
• Result: No mechanism is given for the corticosteroid component in these three indications.
• Funding: Not applicable.

Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.

Where the evidence is mixed

The combination makes the rash look better faster than an azole alone, but does not clear the fungus any better, and the clinical-cure evidence is very low certainty. (Source 16)

• Systematic review, Very low certainty.
• Size: 129 studies with 18,086 participants in the whole review, across 92 comparisons; half of the studies were judged at high risk of bias and the remainder unclear.
• Who: People with proven dermatophyte infection of the body (tinea corporis) or groin (tinea cruris)
• How long: Treatment one week to two months, mostly two to four weeks; follow-up one week to six months.
• Result: Azoles were slightly less effective than azole-and-steroid combination creams for clinical cure immediately at the end of treatment (RR 0.67, 95% CI 0.53 to 0.84, NNT 6, 95% CI 5 to 13) but there was no difference in mycological cure rate (RR 0.99, 95% CI 0.93 to 1.05); certainty rated low for mycological cure and very low for clinical cure.
• Funding: Independent; the authors state there are no financial conflicts of interest.

Limit of this finding: Read the direction of this risk ratio carefully. The 0.67 is azoles compared with the combination, so a figure below 1 means the plain azole did worse on how the rash looked at the end of treatment. On the measure that counts, clearing the fungus, the two were the same (RR 0.99, 95% CI 0.93 to 1.05). Cochrane rated the clinical-cure result very low certainty because of imprecision, indirectness and risk of bias, which means the true effect could be substantially different, and half of the studies in the review were at high risk of bias.

Azoles were slightly less effective in achieving clinical cure compared to azole and steroid combination creams immediately at the end of treatment (RR 0.67, 95% CI 0.53 to 0.84, NNT 6, 95% CI 5 to 13), but there was no difference in mycological cure rate (RR 0.99, 95% CI 0.93 to 1.05). The quality of evidence for these two outcomes was rated as low for mycological cure and very low for clinical cure.

Where the research disagrees

Whether adding a steroid to an antifungal is worth doing at all

• The product label (E. Fougera & Co. Structured Product Label, version 15, 28 July 2026), The manufacturer's registration trials, comparing the combination only against each of its own two ingredients, with the first assessment 3 to 5 days in: In these same clinical studies, patients treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) showed better clinical responses and mycological cure rates when compared with subjects treated with betamethasone dipropionate cream. (Source 13)
• El-Gohary and colleagues, Cochrane 2014, Systematic review of 129 trials and 18,086 participants with GRADE certainty ratings; half the trials at high risk of bias: Although combinations of topical steroids and antifungals are not currently recommended in any clinical guidelines, relevant studies included in this review reported higher clinical cure rates with similar mycological cure rates at the end of treatment, but the quality of evidence for these outcomes was rated very low due to imprecision, indirectness and risk of bias. (Source 14)
• Greenberg and colleagues, Pediatric Dermatology 2002, Narrative literature review of trial data and adverse reactions plus a prescribing cost analysis in one health maintenance organisation: We found that Lotrisone was shown to have the potential to induce many steroid-related side effects and to be less cost effective than antifungal monotherapy. This combination should be used judiciously in the treatment of cutaneous fungal infections and may not be appropriate for use in children. (Source 5)

How much of the harm record the licensed trials can tell you about

• The product label's clinical trial experience section, Registration trials of one to four weeks, reporting symptom-level adverse events: In clinical trials common adverse reaction reported for clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base) was paresthesia in 1.9% of patients. (Source 10)
• The same label's paediatric use section, Open-label trials in 12 to 16 year olds using cosyntropin testing, a laboratory measure of adrenal function rather than a reported symptom, which found suppression in 39.5% and 47.1%: Adverse events consistent with corticosteroid use have been observed in pediatric patients treated with clotrimazole and betamethasone dipropionate cream, 1%/0.05% (base). (Source 3)

How much

• Reference intake: There is no reference intake for a topical prescription medicine; the regimen is set by the prescriber. The label's position, as SPL version 15 effective 28 July 2026, is a thin film twice a day for one week for tinea corporis or tinea cruris and a sufficient amount massaged in twice a day for two weeks for tinea pedis, with the diagnosis reviewed if there is no improvement after that first week or two weeks respectively. (Source 7)
• Upper limit: No upper limit is set by a nutrition body. The label's limits, as a regulatory position, are not more than 45 grams per week, no occlusive dressings, no use longer than 2 weeks for tinea corporis or cruris and no longer than 4 weeks for tinea pedis; it is not to be used on the face or underarms, nor in the diaper area, nor in patients under 17. (Source 7)
• Studied: The adrenal-function study applied 7 grams daily, twice a day, for 14 days to the groin area of 8 normal adult subjects. (Source 4)
• Studied: Each gram of cream contains 10 mg of clotrimazole and 0.64 mg of betamethasone dipropionate, equivalent to 0.5 mg of betamethasone. (Source 17)
• Studied: The children in the Pediatrics case series had been treated with clotrimazole 1% / betamethasone dipropionate 0.05% cream for 2 to 12 months, far beyond the label's 2 to 4 week ceiling. (Source 8)

A common belief, and what the research shows

The belief: A cream with a steroid in it is a stronger antifungal, so it is the better choice for a stubborn fungal rash.

What the research shows: The steroid does not help kill the fungus. Cochrane found that on the measure that counts, clearing the organism, the combination was no better than an azole alone: "there was no difference in mycological cure rate (RR 0.99, 95% CI 0.93 to 1.05)". What it does is suppress the inflammation, which makes the rash look better while the infection continues. That is the mechanism of tinea incognito, and the Cochrane authors are explicit that "combinations of topical steroids and antifungals are not currently recommended in any clinical guidelines". A plain antifungal, by contrast, has a demonstrated effect: Cochrane found that "significantly higher clinical cure rates were seen in participants treated with terbinafine compared to placebo (risk ratio (RR) 4.51, 95% confidence interval (CI) 3.10 to 6.56, number needed to treat (NNT) 3, 95% CI 2 to 4)".

Questions and answers

What is it?

It is one cream containing two drugs. Clotrimazole 1% is an antifungal of the azole family. Betamethasone dipropionate 0.05% is a potent corticosteroid. Each gram of cream holds 10 mg of clotrimazole and 0.64 mg of betamethasone dipropionate, which is equivalent to 0.5 mg of betamethasone, in a water-based cream. In the United States it is prescription-only and licensed for people 17 and over. (Source 17)

What does it do in the body?

The two halves do different things. Clotrimazole blocks a fungal enzyme so the fungus cannot make ergosterol, the sterol its cell membrane needs, and growth stops. Betamethasone dipropionate suppresses inflammation in the skin, which reduces the redness, swelling and itch quickly. The label admits the precise way the steroid helps in tinea is unknown. The same suppression of local immunity is what can let the fungus spread while the skin looks better. (Source 1)

Is it good or bad for you?

Context decides it, and the contexts in which it is a bad idea are wide. For a short course on an inflamed, confirmed tinea of the foot, groin or body in an adult, it clears the appearance a little faster than an antifungal alone. It does not clear the fungus any better, the clinical-cure evidence is very low certainty, and no clinical guideline recommends steroid-antifungal combinations. It is actively harmful where the diagnosis is unconfirmed, on the face or in skin folds, under a dressing or diaper, for more than the licensed 2 to 4 weeks, or in children: adrenal suppression appeared in 39.5% and 47.1% of adolescents in the maker's own trials. (Source 4)

How do you get more of it?

It is a prescription cream in the United States; there is no food, supplement or behaviour that provides it. The amounts studied were a thin film twice a day for one week (tinea corporis or cruris) or a sufficient amount massaged in twice a day for two weeks (tinea pedis), and the adrenal-function study used 7 grams a day for 14 days to the groin. Getting more of it is the wrong instinct: the label caps use at 45 grams a week and at 2 to 4 weeks total. None of this is advice for any reader. (Source 7)

If it is harmful, what reduces it?

Stopping the cream is the documented route. Where it has suppressed the adrenal glands, the label says to withdraw it gradually, apply it less often, or swap to a weaker steroid, and to check with a cosyntropin (ACTH) stimulation test. Where it has masked a fungal infection, the published treatment of tinea incognito is to stop the steroid and then treat the fungus with a proper antifungal. Nothing taken by mouth clears it; it is applied to skin and the exposure ends when application ends, though adrenal effects can outlast it. (Source 4)

Why might someone be low in it or missing it?

The body does not make either drug, so no one can be deficient in them. Someone may not have been given this cream because the diagnosis is not one of the three licensed tinea infections, because they are under 17, because the rash is on the face or in the diaper area, or because their doctor prefers a plain antifungal. Dermatologists in fact prescribe combination agents at only 4.8% of visits for fungal skin disease, against 34.1% for non-dermatologists. The sentence quoted here is the authors' own 1998 conclusion from a survey of United States office visits between 1990 and 1994; that survey counted prescriptions and measured no cure rates, so 'less effective' is their reading of other literature rather than something this study showed. (Source 12)

Which whole foods contain it or feed it?

No whole food contains either drug and no food feeds them; both are manufactured and applied to the skin, not eaten. The cream itself is not for oral, ophthalmic or intravaginal use. None of the four product labels we parsed contains any drug interactions section at all, and none mentions food, alcohol or any dietary supplement. (Source 7)

What happens if you do not have it?

Nothing happens from not having this particular cream, because the antifungal effect can be had without the steroid. In the same Cochrane review, terbinafine beat placebo for clinical cure with a number needed to treat of 3, naftifine beat placebo for mycological cure with a number needed to treat of 3, and clotrimazole 1% alone beat placebo for mycological cure with a number needed to treat of 2. Untreated tinea, on the other hand, persists: the review notes 10% to 20% of the world population is affected by fungal skin infections. (Source 16)

How can you test for it?

Two different tests matter. For the rash itself, the question is whether it really is a dermatophyte: in the paediatric case series the children's diagnosis was confirmed with a potassium hydroxide preparation, and Cochrane notes diagnosis can be made on clinical appearance and confirmed by microscopy or culture. Clinical appearance alone is the step that goes wrong, which is how tinea incognito happens. For the steroid's systemic effect, the test named on the label is the ACTH (cosyntropin) stimulation test, which is what detected adrenal suppression in 39.5% and 47.1% of adolescents; a low morning plasma cortisol was the other signal used. (Source 18)

References

1. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 12.4 Microbiology (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
2. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 1 INDICATIONS AND USAGE (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
3. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 8.4 Pediatric Use (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
4. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 5 WARNINGS AND PRECAUTIONS (5.1 Effects on Endocrine System, 5.2 Diaper Dermatitis, 5.3 Ophthalmic Adverse Reactions) (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
5. Pediatric Dermatology. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. 2002. PMID 11860579, DOI 10.1046/j.1525-1470.2002.00027.x. Read the source
6. Journal of Clinical Medicine. Tinea Incognito: Challenges in Diagnosis and Management. 2024. PMID 38892976, DOI 10.3390/jcm13113267. Read the source
7. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 2 DOSAGE AND ADMINISTRATION (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
8. Pediatrics. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. 2003. PMID 12509578, DOI 10.1542/peds.111.1.201. Read the source
9. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 17 PATIENT COUNSELING INFORMATION (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
10. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 6 ADVERSE REACTIONS (6.1 Clinical Trial Experience, 6.2 Postmarketing Experience) (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
11. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 8.5 Geriatric Use (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
12. Journal of the American Academy of Dermatology. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. 1998. PMID 9674396, DOI 10.1016/s0190-9622(98)70400-1. Read the source
13. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 14 CLINICAL STUDIES (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
14. Cochrane Database of Systematic Reviews. Topical antifungal treatments for tinea cruris and tinea corporis (Authors’ conclusions). 2014. PMID 25090020, DOI 10.1002/14651858.CD009992.pub2. Read the source
15. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 12.1 Mechanism of Action (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
16. Cochrane Database of Systematic Reviews. Topical antifungal treatments for tinea cruris and tinea corporis. 2014. PMID 25090020, DOI 10.1002/14651858.CD009992.pub2. Read the source
17. DailyMed (U.S. National Library of Medicine), Structured Product Label. Clotrimazole and Betamethasone Dipropionate Cream, Section 11 DESCRIPTION (E. Fougera & Co.). SPL version 15, effective 2026-07-28. Read the source
18. Cochrane Database of Systematic Reviews. Topical antifungal treatments for tinea cruris and tinea corporis (Background and Objectives). 2014. PMID 25090020, DOI 10.1002/14651858.CD009992.pub2. Read the source